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Abstract
Background: patients suspected of dementia frequently undergo additional diagnostic testing (e.g. brain imaging or neuro-
psychological assessment) after standard clinical assessment at a memory clinic. This study investigates the use of additional
testing in an academic outpatient memory clinic and how it inﬂuences the initial diagnosis.
Methods: the initial diagnosis after standard clinical assessment (history, laboratory tests, cognitive screening and physical and
neurological examination) and the ﬁnal diagnosis after additional testing of 752 memory clinic patients were collected. We spe-
ciﬁcally registered if, and what type of, additional testing was requested.
Results: additional testing was performed in 518 patients (69%), 67% of whom underwent magnetic resonance imaging, 45%
had neuropsychological assessment, 14% had cerebrospinal ﬂuid analysis and 49% had (combinations of ) other tests. This led
to a modiﬁcation of the initial diagnosis in 17% of the patients. The frequency of change was highest in patients with an initial
non-Alzheimer’s disease (AD) dementia diagnosis (54%, compared with 11 and 14% in patients with AD and ‘no dementia’;
P< 0.01). Finally, after additional testing 44% was diagnosed with AD, 9% with non-AD dementia and 47% with ‘no dementia’.
Conclusion: additional testing should especially be considered in non-AD patients. In the large group of patients with an initial
AD or ‘no dementia’ diagnosis, additional tests have little diagnostic impact and may perhaps be used with more restraint.
Keywords: dementia, memory clinic, MRI, neuropsychological testing, diagnostic accuracy, older people
Introduction
Despite recent advances in diagnostic tests, the accurate diag-
nosis of dementia remains challenging as distinguishing
between normal ageing and dementia, and between the dif-
ferent nosological forms of dementia can prove difﬁcult in
clinical practice. Although no curative treatment exists, an ac-
curate diagnosis at an early stage is becoming increasingly im-
portant as treatment options improve [1].
The evaluation of patients suspected of dementia in a
typical Dutch memory clinic starts with a standard diagnostic
assessment resulting in an initial clinical diagnosis. When the
diagnosis remains uncertain, additional tests are performed,
e.g. brain magnetic resonance imaging (MRI), cerebrospinal
ﬂuid (CSF) biomarker analysis or extensive neuropsychological
assessment (NPA), followed by a ﬁnal diagnosis. Several
studies investigated the diagnostic accuracy of these additional
tests in diagnosing dementia. MRI is recommended to dem-
onstrate or exclude cerebrovascular disease and brain atrophy
[2], and to exclude potentially reversible causes of dementia.
Structural imaging using MRI has been shown to improve
early detection of dementia when added to the standard
diagnostic assessment [3, 4]. The combination of the CSF
biomarkers β-amyloid42, total tau and phosphorylated tau
discriminates Alzheimer’s disease (AD) from other types of
dementia and normal ageing [5–7]. In patients with an
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ambiguous clinical diagnosis, phosphorylated tau has an
added diagnostic value to the standard assessment in the dif-
ferentiation of AD from non-AD [8]. NPA contributes to the
early diagnosis of dementia and to the differentiation of its
various forms, by assessing the proﬁle and extent of the cogni-
tive impairments as well as the inﬂuence of potentially con-
founding factors, such as personality and coping or mood
disturbances [3, 9]. Geroldi et al. concluded that NPA may
have added value to the standard diagnostic assessment [10],
not only for the diagnosis but also providing information that
can be used in the patient’s or caregiver’s care or support.
From the studies cited above MRI, CSF analysis and NPA
are shown to be valuable in diagnosing dementia and dif-
ferentiating between subtypes. However, it remains unclear
which (combinations of ) additional tests are used in clinical
practice and how they are used in determining the ﬁnal diag-
nosis. Preferably, they should only be applied in patients who
beneﬁt from the results as they are in general more burden-
some for the patient and require additional resources.
Therefore, the aim of this study was to analyse whom of the
patients, referred to the memory clinic because of cognitive
complaints, receive additional diagnostic tests and how often
and how these tests resulted in an adjustment of the initial
dementia diagnosis and its nosological classiﬁcation.
Methods
Data on all consecutive patients who visited the outpatient
memory clinic of the Radboud University Medical Center
between 1 January 2007 and 31 December 2010 were col-
lected from the department’s clinical database.
Diagnosis started with a standard diagnostic assessment
including history taking, laboratory tests, physical and neuro-
logical examination and the following cognitive screening
tests: mini-mental state examination (MMSE) [11], the Dutch
version of the revised Cambridge cognitive examination
(CAMCOG-R) [12], neuropsychiatric inventory [13], geriatric
depression scale [14], auditory-verbal learning test (AVLT)
[15], trail making test A (TMTA) [16] and digit span forward
and backward [17]. This standard diagnostic assessment was
done by a registrar in geriatric medicine and supervised by a
geriatrician. Subsequently, during the ﬁrst multidisciplinary
consultation (MDC1), the best possible diagnosis was agreed
upon and the need for additional diagnostics was discussed.
The MDC team consisted of at least a geriatrician, a neuro-
psychologist, an occupational therapist and the registrar
involved in the assessment. When additional testing was per-
formed, a second MDC resulted in the ﬁnal diagnosis.
The initial and ﬁnal diagnoses collected from the memory
clinic database were categorised into three groups: (i) AD,
including possible and probable AD, mixed AD with vascular
dementia and posterior cortical atrophy; (ii) non-AD dementia,
including possible and probable vascular dementia, dementia
with Lewy bodies, frontotemporal dementia, Parkinson demen-
tia, semantic dementia, primary progressive aphasia, Creutzfeldt
Jacob disease and dementia not otherwise speciﬁed; (iii) no de-
mentia, including mild cognitive impairment, vascular cognitive
impairment, neurological and psychiatric conditions and no
diagnosis (i.e. patients with subjective cognitive complaints).
Patient characteristics drawn from the database included
socio-demographic characteristics, presence of relevant
co-morbidity and results of the cognitive screening during the
ﬁrst visit. Data on the use (yes/no) of additional tests were
collected from laboratory and neuropsychologist’s databases.
Statistical analyses
Patients with and without additional tests were compared on
baseline characteristics, cognitive screening results and MDC1
diagnosis using independent t-tests and Chi-square tests. Further
analysis was performed on patients with additional tests. The
frequency of a change in the initial diagnosis was calculated
for the total group as well as for the three diagnosis groups
separately and was compared between these three groups
using Chi-square tests.
Subsequently, the types of additional diagnostic tests were
taken into consideration. AVenn diagram was made to under-
stand which combinations of additional tests were often per-
formed. On the basis of the frequency of co-occurrence of
speciﬁc tests, we identiﬁed four typical clusters. To compare
the change in diagnosis between these additional test clusters
pair-wise a closed testing procedure was used [18, 19].
Furthermore, patients with and without a change in diagnosis
were compared with regard to patient characteristics using the
appropriate statistical procedures.
Results
Over the inclusion period, 767 individual patients were referred
to the memory clinic. After excluding 15 patients with an un-
known diagnosis at MDC1, data of 752 patients were analysed.
Of this group 234 did not undergo additional tests, leaving 518
patients with additional tests. Patients with additional tests were
older (73.7 ± 9.2 versus 71.5 ± 11.7 years; P= 0.006) than
patients without additional tests. Furthermore, patients with
additional tests more frequently had an initial diagnosis of AD
or non-AD dementia and were less frequently in the ‘no demen-
tia’ group (P< 0.001). For more results see Supplementary data
available inAge and Ageing online, Table Appendix S1.
Change in initial diagnosis
Overall, the initial diagnosis changed in 17.2% (n= 89) of the
patients with additional testing. This included 11.4% of the
patients with an initial AD and 13.9% of the patients with an
initial ‘no dementia’ diagnosis. The highest frequency of change
was observed in the non-AD group where 53.6% of the
patients had a change in diagnosis (compared with the other
diagnosis groups, P< 0.001, Table 1). Finally, following add-
itional testing 231 patients (44.6%) were diagnosed with AD,
45 (8.7%) with non-AD and 242 (46.7%) with ‘no dementia’.
An important note is that 29 (53.7%) of the 54 patients with an
initial possible AD changed to probable AD, and therefore
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remained in the AD group but increased in diagnostic certainty.
See Supplementary data available in Age and Ageing online,
Table Appendix S2 for an extensive description of changes.
Types of additional diagnostic tests
Of the total group of patients with additional tests, 66.8% (n=
346) underwent MRI, in 44.8% (n= 232) NPAwas performed,
and 13.7% (n= 71) had CSF analysis. Overall, 216 (41.7%)
patients had more than one of these additional diagnostic tests.
Based on the frequency of co-occurrence of tests, patients were
grouped into four clusters (Figure 1). These clusters were the
following: MRI but no NPA (with/without other tests); NPA
but no MRI (with/without other tests); MRI and NPA (with/
without other tests); any (combination of) other tests. Included
under the heading ‘other tests’ were CSF analysis, occupational
therapy diagnostics (28.1%; n= 102), computed tomography
scan of the brain (4.4%; n= 16) and assessment by a social psy-
chiatric nurse (4.1%; n= 15).
Consequences of additional diagnostic tests
for the initial diagnosis
The frequency of change in diagnosis differed between the
additional test clusters (P = 0.002) (Table 1). In the NPA and
MRI +NPA clusters, changes in diagnosis occurred more
frequently than in the other two clusters. This result was also
found (P< 0.001) when tested solely in patients with an
initial AD diagnosis. For the non-AD and ‘no dementia’
group, no such pattern was found (P = 0.58 and P = 0.25, re-
spectively) (Table 2).
Patients with and without a change in initial
diagnosis
Analysis of patients with and without a change in the initial
diagnosis showed that the patients in the ‘no dementia’ group
with a change in diagnosis were older and performed worse
on the MMSE, CAMCOG-R, TMTA and AVLT (Table 2). In
contrast, patients in the AD group with a change in diagnosis
performed better on the MMSE and the CAMCOG-R than
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Change frequency of the initial diagnosis, in total and per cluster of additional tests
Initial diagnosis Final diagnosis Number of patients (%a)
Total (n= 518) MRIb (n = 190) NPAc (n= 76) MRI +NPAd (n= 156) Other tests (n = 96)
AD n= 210 n= 114 n= 16 n= 31 n= 49
AD 186 (88.6) 107 (93.8) 9 (56.2) 24 (77.4) 46 (93.9)
Non-AD 12 (5.7) 6 (5.3) 2 (12.5) 2 (6.5) 2 (4.1)
No dementia 12 (5.7) 1 (0.9) 5 (31.3) 5 (16.1) 1 (2.0)
Non-AD n= 56 n= 21 n= 9 n= 16 n= 10
AD 17 (30.4) 8 (38.1) 3 (33.3) 4 (25.0) 2 (20.0)
Non-AD 26 (46.4) 11 (52.4) 3 (33.3) 6 (37.5) 6 (60.0)
No dementia 13 (23.2) 2 (9.5) 3 (33.3) 6 (37.5) 2 (20.0)
No dementia n= 252 n= 55 n= 51 n= 109 n= 37
AD 28 (11.1) 5 (9.1) 4 (7.8) 18 (16.5) 1 (2.7)
Non-AD 7 (2.8) 2 (3.6) 2 (3.9) 2 (1.8) 1 (2.7)
No dementia 217 (86.1) 48 (87.3) 45 (88.3) 89 (81.7) 35 (94.6)
Total change 89 (17.2) 24 (12.6) 19 (25.0) 37 (23.7) 9 (9.4)
AD, Alzheimer’s disease; MRI, magnetic resonance imaging; NPA, neuropsychological assessment.
aPercentages are column percentages.
bMRI but no NPA, with/without other tests.
cNPA but no MRI, with/without other tests.
dMRI and NPA, with/without other tests.
Figure 1. Venn diagram, combinations of additional diagnostic
tests (n = 518). Results are displayed as: number of patients, per-
centage. Grey shades represent the grouping for further ana-
lysis: MRI but no NPA (with/without other tests) (n= 190,
36.7%); NPA but no MRI (with/without other tests) (n= 76,
14.7%); both MRI and NPA (with/without other tests) (n=
156, 30.0%) and any (combination of ) other tests (n= 96,
18.6%). MDC, multidisciplinary consultation; MRI, magnetic
resonance imaging; NPA, neuropsychological assessment; CSF,
cerebrospinal ﬂuid.
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AD patients without a change. Typically, AD patients with
a changed diagnosis more frequently underwent NPA,
whereas the patients with the initial AD without a change
more frequently underwent only MRI.
Discussion
The present study investigated the use of additional diagnos-
tic tests and how often and how they changed the initial diag-
nosis in patients with cognitive complaints referred to a
memory clinic. We found that most patients received add-
itional tests. These patients were more frequently diagnosed
with dementia (either AD or non-AD) than patients without
additional tests. The most frequently applied additional tests
were MRI and NPA. Patients with an initial non-AD demen-
tia were most likely to have a change in diagnosis, whereas in
patients with the initial AD or ‘no dementia’ the diagnosis
remained mostly unaltered.
Change in initial diagnosis
Additional tests resulted in a change in diagnosis in 17% of
the patients. The change was highest in patients with an
initial non-AD dementia diagnosis (54%), indicating that this
group was most difﬁcult to diagnose with the standard diag-
nostic assessment. Although the change in diagnosis was low
in the AD group, it resulted in more conﬁdence about the
diagnosis in more than half of patients with possible AD, as
their diagnosis changed to probable AD (Supplementary
data available in Age and Ageing online, Table Appendix S2).
Our study results are in agreement with a study by
Geroldi et al. who found a change in diagnosis in 24% of the
patients with the initial non-AD compared with 7% in
patients with an initial AD diagnosis [10], although their
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2. Baseline characteristics, results of cognitive screening and distribution over the additional diagnostic test clusters
compared between patients with and patients without a change in diagnosis, per initial diagnosis
Variable Number of patients (%a) or mean ± SD
AD Non-AD dementia No dementia
No change
(n= 186)
Change
(n= 24)
P-value No change
(n= 26)
Change
(n= 30)
P-value No change
(n= 217)
Change
(n= 35)
P-value
Age 77.4 ± 7.2 75.0 ± 9.1 0.15 73.6 ± 8.5 74.8 ± 9.0 0.63 70.0 ± 9.7 75.5 ± 7.3 0.002
Female 118 (63.4) 13 (54.2) 0.38 4 (15.4) 18 (60.0) <0.001 101 (46.5) 20 (57.1) 0.24
Comorbidity 118 (63.4) 12 (50.0) 0.20 20 (76.9) 24 (80.0) 0.78 149 (68.7) 26 (74.3) 0.50
Diabetes 35 (18.8) 4 (16.7) 1.00 5 (19.2) 10 (33.3) 0.36 35 (16.1) 8 (22.9) 0.34
Depression 13 (7.0) 2 (8.3) 0.68 0 (0.0) 2 (6.7) 0.49 31 (14.3) 5 (14.3) 1.00
Cardiovascular comorbidityb 106 (57.0) 10 (41.7) 0.16 18 (69.2) 23 (76.7) 0.53 120 (55.3) 20 (57.1) 0.84
MMSEc 19.3 ± 4.7 22.4 ± 4.6 0.003 20.0 ± 4.7 20.6 ± 5.2 0.67 26.5 ± 2.7 24.5 ± 3.0 <0.001
CAMCOG-Rc 71.9 ± 20.3 82. 7 ± 19.4 0.02 77.8 ± 20.7 80.2 ± 19.9 0.66 103.0 ± 14.2 97.1 ± 11.1 0.02
NPId 6.5 ± 5.6 7.6 ± 6.4 0.42 7.9 ± 6.6 5.7 ± 5.2 0.19 4.2 ± 4.5 3.8 ± 4.0 0.70
GDS15d 2.7 ± 2.0 3.1 ± 1.3 0.32 3.1 ± 2.2 3.5 ± 2.5 0.59 3.4 ± 2.9 3.2 ± 2.6 0.62
AVLT totale 21.4 ± 9.4 23.1 ± 12.8 0.44 26.3 ± 12.1 24.5 ± 14.1 0.66 31.9 ± 11.1 27.9 ± 8.3 0.06
AVLT recalle 22.4 ± 6.5 24.4 ± 9.6 0.23 31.2 ± 13.0 28.0 ± 11.8 0.41 32.3 ± 12.8 28.1 ± 10.0 0.09
TMTAe 32.4 ± 20.2 31.9 ± 22.8 0.92 25.8 ± 15.0 30.0 ± 24.6 0.50 43.6 ± 14.0 36.5 ± 16.0 0.01
DSFc 7.1 ± 1.7 7.3 ± 1.4 0.69 6.5 ± 1.7 6.7 ± 1.4 0.66 7.8 ± 1.9 8.3 ± 2.1 0.20
DSBc 3.6 ± 1.7 3.8 ± 1.7 0.62 3.0 ± 1.3 3.4 ± 1.7 0.29 4.8 ± 1.7 4.5 ± 2.2 0.38
Addi tional diagnostic test clusterf <0.001 0.58 0.25
MRIg 107 (57.5) 7 (29.2) 0.01j 11 (42.3) 10 (33.3) j 48 (22.1) 7 (20.0) j
NPAh 9 (4.8) 7 (29.2) <0.001j 3 (11.5) 6 (20.0) j 45 (20.7) 6 (17.1) j
MRI +NPAi 24 (12.9) 7 (29.2) 0.03j 6 (23.1) 10 (33.3) j 89 (41.0) 20 (57.1) j
Other tests 46 (24.7) 3 (12.5) 0.30j 6 (23.1) 4 (13.3) j 35 (16.1) 2 (5.7) j
Number of differential diagnoses 0.9 ± 0.8 1.2 ± 1.0 <0.001 1.3 ± 0.8 1.5 ± 1.0 0.43 1.1 ± 0.9 1.6 ± 0.9 0.003
AD, Alzheimer’s disease; MMSE, Mini-Mental State Examination; CAMCOG-R, Dutch version of the revised Cambridge cognitive examination; NPI,
neuropsychiatric inventory; GDS15, geriatric depression scale-15; AVLT, auditory-verbal learning test; TMTA, trail making test part A; DSF, digit span forward; DSB,
digit span backward; MRI, magnetic resonance imaging; NPA, neuropsychological assessment.
aPercentages are column percentages.
bConsisting of hypertension, cardiovascular disease and hypercholesterolaemia/hypertriglyceridaemia.
cA low score is abnormal. Range: MMSE (0–30), CAMCOG-R (0–107), DSF (0–16), DSB (0–14).
dA high score is abnormal. Range: NPI (0–144), GDS15 (0–15).
eStandardized T-scores (normative mean = 50, SD = 10).
fClosed testing procedure.
gMRI but no NPA, with/without other tests.
hNPA but no MRI, with/without other tests.
iMRI and NPA, with/without other tests.
jP-value for testing the change rate of the specific diagnostic cluster against the change rate among the other three diagnostic clusters combined. If the P-value is not
reported, this is because the overall Chi-square test whether change rates differed among the four diagnostic clusters was not significant (closed testing) [18, 19].
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absolute change percentages were lower. However, the
patients in their study were already more severely affected,
making it easier to agree upon a diagnosis during standard
diagnostic assessment. Furthermore, all their patients
received both MRI and NPA regardless of the initial diagno-
sis, whereas in our study the necessity (most likely based on a
lack of diagnostic certainty) of requesting additional tests was
considered individually. This probably resulted in the larger
percentage of change in diagnosis if additional tests were
applied. Our study therefore provides insight in the way add-
itional tests are applied on an individual basis and how they
affect the change frequency in an outpatient memory clinic.
Types of additional diagnostic tests and their
consequences for the initial diagnosis
MRI and NPA were the most frequently requested tests.
Noteworthy is that in more than half of the patients with an
initial AD diagnosis MRI was requested as a single test.
In this speciﬁc group, only 6% had a change in diagnosis,
meaning that MRI was conﬁrmatory rather than required to
establish the diagnosis. Furthermore, we noticed that patients
initially diagnosed with a form of dementia who underwent
at least NPA most frequently changed to ‘no dementia’,
whereas patients who only had MRI most frequently
switched between AD and non-AD dementia. This differ-
ence can be explained by the purpose for which the addition-
al tests are requested. NPA is known for its accuracy in
determining the proﬁle and severity of cognitive complaints
(differentiate between dementia and no dementia), whereas
MRI is used to show structural abnormalities of the brain
(distinguish AD from other forms of dementia) [3].
In contradiction to our results, Chui et al. [20] found that
diagnoses changed more often after neuroimaging (28%)
than after NPA (11%). The difference in results can be due
to the large number of patients in the study of Chui et al. in
whom other lesions (e.g. treatable lesions and infarcts) were
diagnosed after neuroimaging, making their study population
less comparable with ours. Other studies that investigated
changes in diagnosis reported values of 26% when NPA and
MRI were both added to the standard assessment [3], and
24% for neuroimaging alone [21]. The overall conclusion in
these papers was that a standard clinical assessment alone is
insufﬁcient for optimal diagnosis in a selection of patients.
The current data showed that although additional diagnostics
are deﬁnitely useful in non-AD, for a large group of patients
with AD or ‘no dementia’ these tests were in practice mainly
used to conﬁrm the initial diagnosis.
Patients with and without a change in initial
diagnosis
Patients with a change in diagnosis had more atypical results
on cognitive screening tests, i.e. better performance than
would be expected in patients with an initial dementia diag-
nosis and worse performance in the ‘no dementia’ patients
indicating a lack of concordance between symptom
presentation and cognitive testing. In other words, the diag-
nostic uncertainty was probably higher in these patients and
therefore explained the change in diagnosis. Also, a longer
list of differential diagnoses was formulated in patients with a
change, which is another indicator of diagnostic uncertainty
(Supplementary data available in Age and Ageing online,
Table Appendix S1). In summary, not only the additional
tests but also the diagnostic uncertainty contributed to a
change in diagnosis. Therefore, it seems likely that diagnostic
uncertainty and the choice of additional tests are associated.
In future research, it is thus important to report the level of
diagnostic uncertainty as it may be helpful to understand
how the diagnostic process results in a certain diagnosis.
Furthermore, explicitly taking into account the diagnostic un-
certainty in the decision to perform additional testing can in-
crease the awareness of clinicians on why they want
additional testing and for which patients it will and for which
patients it will probably not be beneﬁcial. The statistically sig-
niﬁcant difference in sex of patients with initially non-AD
type dementia diagnosis has no straightforward interpret-
ation: perhaps it is a chance ﬁnding.
Limitations
Although our study design is distinctive from the current
literature, using data from a clinical routine database has its
limitations as well. First, in patients for whom it was decided
that additional testing was unnecessary, the possible inﬂuence
of additional tests on the initial diagnosis could not be
assessed. Especially in the group of patients with a ﬁnal ‘no
dementia’ diagnosis at MDC1 this could result in denial of
early intervention. However, as the decision not to request
additional tests in this group was made deliberately by the
MDC team, it seems plausible that additional tests would
have had a minimal impact on the diagnosis. Furthermore, as
none of the diagnoses were validated by post-mortem neuro-
pathological examination [22] or another reference standard,
we do not know if the ﬁnal diagnosis is in fact correct and
when the initial diagnosis changed, if it has improved.
Nevertheless, for the purpose of this study, these shortcom-
ings do not outweigh the beneﬁts of a database with a study
population that resembles the actual patient population and
its speciﬁc prior probability of dementia [23], and the ability
to systematically assess the clinical use of these complex diag-
nostic tools.
Conclusion
The present study indicated that the occurrence of a change
in the initial diagnosis after additional testing differed consid-
erably between groups of memory clinic patients. Additional
examination should especially be considered in patients sus-
pected of non-AD, whereas in the large group of patients
with an uncomplicated picture of AD or ‘no dementia’ add-
itional tests may perhaps be requested with more restraint.
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Key points
• The majority of patients referred to the memory clinic
receive additional diagnostic tests.
• Brain imaging with MRI and NPA are the most frequently
requested additional tests.
• After additional tests more than half of patients with an
initial non-AD dementia have a change in diagnosis.
• In patients with initial AD or ‘no dementia’ the diagnosis
remains unaltered in most cases after additional tests.
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